



GENERAL - APIs

| Sr.No. | PRODUCT NAME | GRADES | DOCUMENTATION |
|--------|-------------------------------------|--------------|------------------|
| 1 | Abacavir Sulfate | USP | APIMF/EDMF |
| 2 | Atazanavir Sulfate | IH | APIMF/USDMF |
| 3 | Tenofovir Alafenamide Mono Fumarate | IH | APIMF/USDMF/EDMF |
| 4 | Tenofovir Alafenamide Hemi Fumarate | IH | APIMF/USDMF/EDMF |
| 5 | Tenofovir Disoproxil Fumarate | IH | DMF |
| 6 | Oseltamivir Phosphate | IP/IH/USP/EP | DMF |
| 7 | Dabigatran Etxylate Mesylate | IH | DMF |
| 8 | Bictegravir | IH | DMF |

ONCOLOGY - APIS

| Sr.No. | PRODUCT NAME | GRADES | DOCUMENTATION |
|--------|---|-----------|----------------|
| 1 | Capecitabine | USP/EP/IP | USDMF/EDMF/CEP |
| 2 | Dasatinib (Amorphous , Anhydrous form) | EP | DMF/EDMF |
| 3 | Erlotinib (Form A & B) | EP | DMF |
| 4 | Enzalutamide | IH | DMF |
| 5 | Gefitinib | EP/IP | DMF/EDMF |

Cdymax (India) Pharma Pvt. Ltd.

77D & 116/117, KIADB Industrial Area Jigani, Bangalore - 560 105 INDIA

Contact: Gaurav Chaturvedi –GM Sales & Marketing

Mobile: +91-9019317788 Email: gaurav@cdymax.in

| 6 | Imatinib Mesylate (Alpha,Beta,Base) | USP/EP/IP | USDMF/EDMF |
|--|---------------------------------------|-----------------|---------------------------------------|
| 7 | Pazopanib HCL | IH | DMF |
| 8 | Pemetrexed Disodium (2.5 & 7 hydrate) | EP | DMF/EDMF |
| 9 | Sorafenib (form 1 and form 3) | IH | TP |
| 10 | Sunitinib Malate and Base | IH | DMF |
| 11 | Palbociclib | IH | DMF |
| 12 | Nilotinib HCL dihydrate | IH | DMF |
| 13 | Abiraterone Acetate | IH | DMF |
| PIPELINE PRODUCTS -APIS | | | |
| Sr. No. | PRODUCT NAME | Timeline | DOCUMENTATION |
| 1 | Ibrutinib | Q1-2022 | With All Regulatory Documents support |
| 2 | Olaparib | Q1-2022 | With All Regulatory Documents support |
| 3 | Ribociclib AZT-III -Innovative form | Q1-2022 | With All Regulatory Documents support |
| 4 | Ruxulitinib Phoshate | Q1-2022 | With All Regulatory Documents support |
| 5 | Alectinib | Q1-2022 | With All Regulatory Documents support |
| 6 | Eltrombopag Diolamine | Q1-2022 | With All Regulatory Documents support |
| 7 | Daclatasvir | Q2-2022 | With All Regulatory Documents support |
| 8 | Elagolix | Q2-2022 | With All Regulatory Documents support |
| 9 | Isavuconazonium sulfate | Q1-2022 | With All Regulatory Documents support |
| 10 | Vitamin B1 (Thiamine HCL) | Q2-2022 | With All Regulatory Documents support |
| *** Products under Patent are not offered for Sales until Patent Expiration in the Relevant Country | | | |

For Sales Enquiries, Kindly reach below contact Person

Name: Gaurav Chaturvedi
Designation: General Manager Marketing
Mobile: +91-9019317788
Email: Gaurav@cdymax.in

Cdymax (India) Pharma Pvt. Ltd.
77D & 116/117, KIADB Industrial Area Jigani, Bangalore - 560 105 INDIA
Contact: Gaurav Chaturvedi –GM Sales & Marketing
Mobile: +91-9019317788 Email: gaurav@cdymax.in